Figure 7.
Antithrombotic effects of uPA-PLTs. (A) Schematic representation of the in vivo thrombosis model. Day-12 CD34+ MKs that had been loaded with scuPA or uPAT for 24 hour were injected in NSG or NSG/VWF mice. Infused MKs are trapped in the lung vasculature in which they release PLTs.49 Photochemical intravascular injury is induced by injection of Rose Bengal and exposure to a 540 nm laser.50 Human PLT released from CD34+ MKs (green) are incorporated into the nascent thrombus also containing murine PLTs (red). (B) Area under the curve (AUC) of blood flow over the first 40 minutes after injury. The genotype of the recipient mice and the infusion of CD34+ MKs are shown in the abscissa as well whether the MKs had been incubated with scuPA or uPAT. The mean ± 1 SD and the number of independent experiments are shown in each bar. P values show outcomes in NSG/VWF studies compared with NSG control studies (orange bar) as determined by ordinary 1-way ANOVA analysis. (C) AUC of blood flow over the first 40 minutes after injury. The genotype of the recipient mice and the infusion of CD34+ MKs without or along with scuPA (2 mg/kg) are shown in the abscissa as well as whether the MKs had been incubated with scuPA. The mean ± 1 SD and the number of independent experiments are shown in each bar. P values show outcomes in NSG/VWF studies compared with NSG control mouse (purple bar) as determined by ordinary 1-way ANOVA analysis.